MassDevice Q&A: Jean-Marc Wismer

July 14, 2009 by Brian Johnson

The CEO of Switzerland's Sensimed looks to peel back the lid on glaucoma testing.

You literally cannot see glaucoma coming.

Although it's one of the leading causes of blindness in the world, frighteningly little is known about a disease group that affects 4 percent of the world's population over the age of 40. No cure is on the horizon. And due to the insidious nature of the disease, which stars gradually affecting sight from the periphery, most people don't even know they're suffering from glaucoma until it's too late.

Swiss diagnostics company Sensimed AG sees this mysterious disease as a real opportunity.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

The FDA is ramping up its cybersecurity labs and may start rejecting insecure technologies sooner than you think.

Transcend Medical CEO Brian Walsh tells MassDevice.com why his company's CyPass micro-stent is poised to revolutionize the treatment of glaucoma.

Integrity Applications looks beyond optical sensors with its GlucoTrack Model DF-F, which uses ultrasonic, electromagnetic and thermal technology to measure physiological changes associated with blood glucose levels.

Former NBA player Jonathan Bender tries his hand at entrepreneurship, aiming to bring the physical therapy device he invented to the U.S. market.

Battelle engineering manager Melissa Masters tells MassDevice.com how insights ranging from national security to aeronautics can inform the creation of disruptive new medical devices.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp